Resources

Minister for Skills Baroness Jacqui Smith chose Precision Health Technology Accelerator (PHTA) as the setting for the launch of a new Higher Technical Qualification (HTQ) designed to tackle the UK’s growing medtech skills shortage.

As 2025 draws to a close, the UK life sciences and biotech sector looks back on a year of challenge, progress, collaboration and impact. From funding headwinds and policy uncertainty to major fundraising achievements, government commitments and rising global confidence in the UK, BIA highlights the key developments shaping the sector and sets the stage for a strong 2026.

eXmoor Pharma and UCL have launched a new partnership to strengthen the pathway from academic research to GMP delivery, giving UCL innovators earlier access to CMC expertise, development capabilities and clinical manufacturing support to accelerate the translation of cell and gene therapies.

Proceeds will enable generation of full clinical data from ongoing Phase 1 study of TROCEPT-01 (ATTR-01), its lead programme in advanced solid tumours, and progression of TROCEPT-02 (ATTR-02) into the clinic.

In this blog, Blood Cancer UK reflects on a year of partnership with BIA — from raising vital funds and forging new connections in life sciences, to amplifying the voice of people affected by blood cancer across the UK.

Precision treatments tackling the hardest-to-treat cancers set to be produced from hundreds of tonnes of reprocessed uranium from nuclear reactors

Our final blog of 2025 celebrates some excellent fundraising news to close the year, while highlighting key opportunities to engage with and shape the UK life sciences agenda — including the development of UK engineering biology, data policy, a cross-cancer research policy position and salary benchmarking.

Particology has been selected for an £8.2 million Government-funded research consortium to make the manufacture of medicines more efficient and sustainable. 

Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, today announced a further strengthening of its senior leadership with Ian Coyne joining the Managing Partners group. In addition to this strategic leadership expansion, the firm further refined the structure of its Senior Leadership team, with Joe Coulter assuming a new role as Chief Business Officer (CBO) and Charlotte James being promoted to Chief Operating Officer (COO).

Relation today announced a further $26 million investment from existing investors NVentures (NVIDIA’s venture capital arm) and leading deeptech investors DCVC and Magnetic Ventures.

Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in the advancement of the cell and gene therapy industry, has established a consortium to demonstrate how safety tests that detect potentially dangerous undifferentiated residual cells, which can affect product purity, could be applied to a range of a cell therapies.

Scancell Holdings, the developer of active immunotherapies to treat cancer, announces updated positive data from the SCOPE Phase 2 trial of iSCIB1+ in combination with ipilimumab and nivolumab, current standard of care (SoC).

Relation Therapeutics has announced a multi-program, strategic collaboration with Novartis to discover and advance novel targets for atopic diseases.

Four projects aimed at identifying the most promising repurposed drug candidates to treat motor neuron disease (MND) have been launched by the self-funded medical research organisation, LifeArc.

Cellular Origins, a TTP company that enables the manufacturing of cell therapies at scale, has completed a $40 million (EUR 34.3 million) over-subscribed Series A round.

Oxford Nanopore Technologies has appointed Francis Van Parys as Chief Executive Officer (CEO). Francis will join the Company and the Board as an Executive Director on 2 March 2026.

Poolbeg Pharma will act as the lead business partner, alongside Johnson & Johnson and other partners, on The University of Manchester and The Christie NHS Foundation Trust research programme which will facilitate wider research into cancer immunotherapy-induced CRS and the safer delivery of these treatments.